



Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis

December 1, 2021

End-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC)

PARIS, France, December 1, 2021 – 7:30 pm (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announced that the US Food and Drug Administration (FDA) recently provided valuable feedback in the context of the end-of-phase-2 meeting with guidance and a path forward to bring ABX464 into phase 3 clinical testing for the treatment of ulcerative colitis and subsequent potential marketing authorization submission and commercialization. This includes comments on study design, dose selection and the statistical analysis plan.

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: *“The FDA feedback on the end-of-phase-2 meeting with the regulator’s expectations and guidance for the ABX464 phase 3 study design in ulcerative colitis is a very important step for Abivax. We are now incorporating the FDA feedback into the study protocols and, following the scientific advice of the EMA, will work towards the final clinical study designs and operational set-up. 2022 will be an inflection point for Abivax taking our lead drug candidate ABX464 one important step further towards potential marketing authorization and commercialization, starting in North America, Europe and Japan.”*

The scientific advice meeting with the European Medicines Agency (EMA) is scheduled for early Q1 2022. Taking into account the guidance from FDA and potential recommendations from EMA, Abivax intends to finalize the phase 3 study design and update its IND for ABX464 for the treatment of ulcerative colitis in Q1 2022. Subject to regulatory clearance, Abivax plans to enroll the first patient into its pivotal program in Q2 2022.

About Abivax (www.abivax.com)

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax

Communications

Regina Jehle

regina.jehle@abivax.com

+33 6 24 50 69 63

Investors

LifeSci Advisors

Ligia Vela-Reid

lvela-reid@lifesciadvisors.com

+44 7413 825310

Press Relations & Investors Europe

MC Services AG

Anne Hennecke

anne.hennecke@mc-services.eu

+49 211 529 252 22

Public Relations France

Actifin

Ghislaine Gasparetto

ggasparetto@actifin.fr

+33 6 21 10 49 24

Public Relations France

DGM Conseil

Thomas Roborel de Climens

thomasdeclimens@dgm-conseil.fr

+33 6 14 50 15 84

Public Relations USA

Rooney Partners LLC

Jeanene Timberlake

jtimberlake@rooneypartners.com

+1 646 770 8858

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and ethics committees of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC, clinical data, Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.

This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.